GSK, Novartis ink 'supercomplex' $26.65B three-way transaction
By Nuala Moran
Tuesday, April 22, 2014
LONDON – Novartis AG and Glaxosmithkline plc are exchanging assets in a three-way, "supercomplex" deal that will see Novartis paying $16 billion for GSK's marketed oncology portfolio, while GSK acquires Novartis' vaccines arm for $5.25 billion.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.